SCH 56582
Latest Information Update: 26 Jul 2001
At a glance
- Originator Schering-Plough
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Jul 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 02 Jun 1998 Preclinical development for Cancer in USA (Unknown route)
- 27 May 1998 New profile